Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00625248 |
Recruitment Status :
Completed
First Posted : February 28, 2008
Last Update Posted : June 24, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Bleeding | Drug: Antithrombotics |
- To evaluate bleeding risk in interventional procedures in patients with or without antiplatelet and/or anticoagulant therapy.
- To evaluate differences in outcomes in patients not receiving any anticoagulant or antiplatelet therapy compared to patients receiving various types of drugs with anticoagulant or antiplatelet therapeutic effects.
- To evaluate and compare the adverse event profiling all patients.
Study Type : | Observational |
Actual Enrollment : | 12000 participants |
Time Perspective: | Prospective |
Official Title: | A Prospective Evaluation of Bleeding Risk of Anticoagulant and Antiplatelet Therapy for Interventional Techniques |
Study Start Date : | February 2008 |
Actual Primary Completion Date : | January 2009 |
Actual Study Completion Date : | January 2010 |

Group/Cohort | Intervention/treatment |
---|---|
no anthithrombotic
procedures where there were no antithrombotics
|
Drug: Antithrombotics
With or without or discontinuted use of Antithrombotics
Other Name: anticoagulant or antiplatelet drugs |
Antithrombotic - continued
patients who are on antithrombotics
|
Drug: Antithrombotics
With or without or discontinuted use of Antithrombotics
Other Name: anticoagulant or antiplatelet drugs |
Discontinued Antithrombotic
Patients who were on antithrombotics but have been discontinued
|
Drug: Antithrombotics
With or without or discontinuted use of Antithrombotics
Other Name: anticoagulant or antiplatelet drugs |
- To evaluate for differences between the patients undergoing interventional techniques with or without anticoagulant or antiplatelet therapy. [ Time Frame: 24 months ]
- To assess adverse events in all patients. [ Time Frame: 24 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Subjects undergoing interventional techniques. Subjects who were able to give voluntary, written informed consent.
Exclusion Criteria:
- All those things, patients on heparin, dextran, and low molecular heparin

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00625248
United States, Kentucky | |
Pain Management Center of Paducah | |
Paducah, Kentucky, United States, 42003 |
Principal Investigator: | Laxmaiah Manchikanti, MD | Ambulatory Surgery Center, Paducah |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Laxmaiah Manchikanti, MD, Medical Director, Pain Management Center of Paducah |
ClinicalTrials.gov Identifier: | NCT00625248 |
Other Study ID Numbers: |
protocol 18 |
First Posted: | February 28, 2008 Key Record Dates |
Last Update Posted: | June 24, 2013 |
Last Verified: | June 2013 |
Hemorrhage Pathologic Processes Anticoagulants Platelet Aggregation Inhibitors |